Study of CEP-9722 as Single-Agent Therapy and as Combination Therapy With Temozolomide in Patients With Advanced Solid Tumors

Solid Tumor Clinical Trial

Official title:

An Open-Label Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of CEP-9722 (a PARP-1 and PARP-2 Inhibitor) as Single-Agent Therapy and as Combination Therapy With Temozolomide in Patients With Advanced Solid Tumors

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00920595
• Other study ID #: C9722/1065/PK/FR-UK
• Secondary ID: EudraCT number:
• Status: Completed
• Phase: Phase 1
• First received: June 11, 2009
• Last updated: August 14, 2012
• Start date: June 2009
• Est. completion date: October 2011

Study information

• Verified date: August 2012
• Source: Teva Pharmaceutical Industries
• Contact: n/a
• Is FDA regulated: No
• Health authority: France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)United Kingdom: Medicines and Healthcare Products Regulatory Agency
• Study type: Interventional

Clinical Trial Summary

An open-label study to evaluate the safety, pharmacokinetics, and pharmacodynamics of CEP-9722 as single-agent therapy and as combination therapy with temozolomide in patients with advanced solid tumors.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 26
• Est. completion date: October 2011
• Est. primary completion date: October 2011
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• The patient has a histologically or cytologically confirmed malignant advanced solid tumor considered unresponsive or poorly responsive to accepted treatment modalities.

• The patient has adequate hematologic assessments and adequate renal and hepatic functions as specified in the study protocol.

• The patient has measurable or nonmeasurable disease documented with an appropriate method of evaluation according to disease characteristics.

• The patient has had no chemotherapy for at least 3 weeks and has resolution of prior sequelae. If the patient has had prior curative radiation or prior treatment with nitrosoureas, a minimum of 4 weeks and 6 weeks, respectively, must have elapsed before treatment with CEP-9722.

• The patient has had no immunotherapy, including monoclonal antibody therapy, for at least 4 weeks and no hormonotherapy for at least 1 week, with the exception of patients with prostate cancer, who may continue hormonal therapy.

• The patient has a European Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.

• The patient has a life expectancy of 12 weeks or more.

• Agreement by women of childbearing potential (not surgically sterile or 2 years postmenopausal) to use a medically accepted method of contraception and continue the use of this method for the duration of the study and for 90 days after participation in the study. Acceptable methods of contraception include abstinence, barrier method with spermicide, intrauterine device (IUD), or steroidal contraceptive (oral, transdermal, implanted, and injected) in conjunction with a barrier method.

• Agreement by men not surgically sterile or who are capable of producing offspring to practice abstinence or use a barrier method of birth control, and continue use of this method for the duration of the study and for 6 months after participation in the study.

Exclusion Criteria:

• The patient has a primary brain tumor whose disease requires a systematic premedication with anticonvulsive agents.

• The patient has baseline cardiac abnormalities outside of the specified study parameters.

• The patient has clinically symptomatic recurrent/progressive brain metastases within 4 weeks (stable sequelae are acceptable).

• The patient has previous hypersensitivity reactions to 1 of the components of CEP-9722, temozolomide, or dacarbazine.

• The patient is a pregnant or breast-feeding woman. (Any women becoming pregnant during the study will be withdrawn from the study.)

• The patient is participating in another interventional clinical study at the time of enrollment, has participated in another interventional clinical study within 4 weeks prior to enrollment, or the patient has previously been already enrolled in this study.

• The patient has an active gastroduodenal ulcer, uncontrolled high blood pressure, uncontrolled diabetes mellitus, or uncontrolled angina pectoris; has had a recent myocardial infarction; has had a cerebrovascular event within 6 months prior to study entry; or has pre-existing coagulopathy.

• The patient has a concomitant uncontrolled infection or severe systemic disease.

• The patient has a known nephropathy or hepatopathy.

• The patient is receiving concurrent treatment with an antineoplastic agent other than temozolomide.

• The patient has had previous treatment with another PARP inhibitor.

• The patient is unable to swallow capsules.

• The patient has taken any medications which are contraindicated as specified in the study protocol.

• The patient has any serious or uncontrolled nonmalignant medical disorder or psychiatric disorder.

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Solid Tumor

Intervention

Drug:
• CEP-9722
Starting dose of CEP-9722 is 150 mg/day (total dose). The study consists of a 14-day cycle of CEP-9722 alone, and at least one 28-day cycle of CEP-9722 plus temozolomide (150 mg/m2/day on Days 1-5). Patients who are receiving clinical benefit may receive subsequent cycles of study drug treatment.

Locations

Country	Name	City	State
France	Cephalon Investigational Site	Nantes
United Kingdom	Cephalon Investigational Site	Newcastle upon Tyne

Sponsors (1)

Lead Sponsor	Collaborator
Cephalon

Countries where clinical trial is conducted

France,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Determination of Maximum Tolerated Dose (MTD) upon Dose Limiting Toxicities (DLT) data		Up to 42 days	Yes
Secondary	Pharmacokinetic parameters		Days 1 and 5 of Cycle 1 and on Day 5 of Cycle 2	No
Secondary	Pharmacodynamics assay		Days 1, 5, and 8 of both Cycle 1 and Cycle 2	No
Secondary	Efficacy - will be assessed by the proportion of patients who achieve tumor response during the study		A 14-day cycle and at least one 28-day cycle	No